Sorted By Test Name - Mayo Medical Laboratories

UPGDW
31892
obstruction. Hemoglobin: Hemoglobinuria is an indicator of intravascular hemolysis. The test is equally
sensitive to myoglobin as to hemoglobin (Hgb). The presence of Hgb, in the absence of RBCs, is
consistent with intravascular hemolysis. RBCs may be missed if lysis occurred prior to analysis; the
absence of RBCs should be confirmed by examining a fresh specimen. The presence of myoglobin may
be confirmed by MYOU/9274 Myoglobin, Urine. Reducing substances: Urine can contain a variety of
reducing substances (sugars [glucose, galactose, sucrose, fructose, lactose, maltose], ascorbic acid, drugs,
etc), compounds so termed because of their ability to reduce cupric ions. The primary reducing substances
of medical significance are the sugars, glucose (diabetes) and galactose (galactosemia). Other sugars may
be found but are not of clinical significance. Because glucose also is detected by glucose-specific dipstick
reagents, the test for reducing substances is performed to detect galactose.
Reference Values:
Descriptive report
Clinical References: 1. Grossfeld GD, Litwin MS, Wolf JS, et al: Evaluation of asymptomatic
microscopic hematuria in adults: the American Urological Association best practice policy--part I:
definition, detection, prevalence, and etiology. Urology 57:599-603, 2001
Uroporphyrinogen Decarboxylase (UPG D), Washed
Erythrocytes
Clinical Information: Porphyria cutanea tarda (PCT) is the most common porphyria, affecting
approximately 1 in 25,000 individuals in the United States. PCT results from a partial deficiency of
hepatocyte and/or erythrocyte uroporphyrinogen decarboxylase (UPGD), the fifth enzyme in heme
biosynthesis. PCT is classified into 3 subtypes. The most frequently encountered is type I which is a
sporadic or acquired form and is typically associated with concomitant disease or other precipitating
factors. Patients exhibit normal UPGD activity in erythrocytes and decreased hepatic activity. This differs
from type II PCT in which patients exhibit approximately 50% activity in erythrocytes. PCT type II
accounts for about 20% of cases and is inherited in an autosomal dominant manner with low penetrance.
Type III is a rare familial form seen in